BLFS

NEUTRALM&A

BioLife Solutions, Inc.

2026-09-14

Price

$35.43

+1.37%

This is the 2026-09-14 snapshot — the signals and analysis for BLFS as of this single trading day.

View full BLFS research hub →

Score6.0Priority

Signals3/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 6

Volume0.5xvs 20d avg

Analysis

BioLife Solutions (BLFS) is trading in a tight, low-volume consolidation because it is firmly anchored by its pending acquisition by Repligen. The recent definitive merger proxy filing for an October 5, 2026 shareholder vote has shifted the stock's dynamics purely into merger arbitrage, explaining the PERFECT_STACK and SELLER_FATIGUE signals as institutional deal-pegging rather than organic accumulation. Supported by a RISK_ON macro regime with exceptionally tight credit spreads (0.80%), the market is pricing in near-zero financing or deal-break risk, providing high conviction that the acquisition will close smoothly.

Fired Signals

GOLDEN CROSSMARKET LEADERPERFECT STACKSELLER FATIGUE

Key Takeaways

BLFS is currently a pure merger arbitrage play tied to Repligen, providing a stable, low-beta holding through the October 5 vote.
The primary risk is a sharp decline in Repligen's (RGEN) stock price, which would drag down the implied value of the stock-and-cash deal.
Watch for the October 5 shareholder vote and maintain $34.92 as a strict risk-management level against unforeseen deal complications.

← Back to 2026-09-14 View Full BLFS History →Yahoo Finance &nearr;